Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Menne

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
MMW Fortschritte Der Medizin|November 7, 2008
[German physicians study new device. Pacemaker for therapy of hypertension? (interview by Dr. Thomas Meissner)]Jan Menne
Kidney International|May 24, 2020
Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?Jan Menne
Journal of Hypertension|December 11, 2012
Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance?Christos Chatzikyrkou, Jan Menne
Nature Reviews. Nephrology|September 11, 2013
Diabetes: Legacy effects of RAS blockade in diabetes mellitusChristos Chatzikyrkou, Jan Menne
Expert Review of Cardiovascular Therapy|October 27, 2012
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetesChristos Chatzikyrkou, Jan Menne
Der Nephrologe|July 6, 2021
[SGLT2 inhibitors: What is new?]Eva Dumann, Jan Menne
Mayo Clinic Proceedings|December 11, 2012
Olmesartan and intestinal adverse effects in the ROADMAP studyJan Menne, Hermann Haller
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Fixed-dose lercanidipine/enalapril for hypertensionJan Menne, Hermann Haller
Journal of Hypertension|July 10, 2010
Awareness and behaviour of European physicians in relation to microalbuminuria and organ damage: an ESH-endorsed surveyHermann Haller, Jan Menne, Giuseppe Mancia
Medizinische Klinik (Munich, Germany : 1983)|August 25, 2009
[Hypertension 2007-2008]Christos Chatzikyrkou, Jan Menne, Hermann Haller
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
MMW Fortschritte Der Medizin|November 7, 2008
[German physicians study new device. Pacemaker for therapy of hypertension? (interview by Dr. Thomas Meissner)]Jan Menne
Kidney International|May 24, 2020
Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?Jan Menne
Journal of Hypertension|December 11, 2012
Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance?Christos Chatzikyrkou, Jan Menne
Nature Reviews. Nephrology|September 11, 2013
Diabetes: Legacy effects of RAS blockade in diabetes mellitusChristos Chatzikyrkou, Jan Menne
Expert Review of Cardiovascular Therapy|October 27, 2012
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetesChristos Chatzikyrkou, Jan Menne
Der Nephrologe|July 6, 2021
[SGLT2 inhibitors: What is new?]Eva Dumann, Jan Menne
Mayo Clinic Proceedings|December 11, 2012
Olmesartan and intestinal adverse effects in the ROADMAP studyJan Menne, Hermann Haller
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Fixed-dose lercanidipine/enalapril for hypertensionJan Menne, Hermann Haller
Journal of Hypertension|July 10, 2010
Awareness and behaviour of European physicians in relation to microalbuminuria and organ damage: an ESH-endorsed surveyHermann Haller, Jan Menne, Giuseppe Mancia
Medizinische Klinik (Munich, Germany : 1983)|August 25, 2009
[Hypertension 2007-2008]Christos Chatzikyrkou, Jan Menne, Hermann Haller
Pageof 12